Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $10.01 which represents a decrease of $-0.54 or -5.12% from the prior close of $10.55. The stock opened at $10.64 and touched a low of $9.

Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran.

Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also significantly reduced its price target to $11.

Morgan Stanley downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $11, down from $56. The firm now